Treatment of End Stage Heart Failure Related to Cardiac Amyloidosis

Hasin, Tal; Raichlin, Eugenia; Dispenzieri, Angela; SudhirKushwaha,

doi:10.5772/55553

Cited by 1 publication

(1 citation statement)

References 159 publications

(156 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Дигоксин противопоказан больным первичным амилоидозом с синусовым ритмом [16,43], а его применение для контроля ЧСС при фибрилляции предсердий рядом авторов признается небезопасным [29,44], так как было показано, что дигоксин связывается с фибриллами амилоида, в результате чего его внутрисердечный уровень может быть повышен с развитием токсических эффектов даже при «терапевтической» концентрации в A r t i c l e i n P r e s s [16].…”

Section: A R T I C L E I N P R E S Sunclassified

Heart involvement in AL-amyloidosis. Current state of the issue

et al. 2019

View full text Add to dashboard Cite

AL cardiac amyloidosis is a relatively rare disorder that belongs to the group of infiltrative cardiomyopathies. Diagnosis of primary amyloidosis is challenging due to many unspecific symptoms and sings, which often leads to late diagnosis when treatment options are limited. Primary amyloidosis particularly needs to be excluded in patients with heart failure with preserved ejection fraction. Therapy in cardiac amyloidosis has to main vectors: 1) chemotherapy to eliminate amyloidogenic plasmatic cells 2) heart failure treatment. The main challenge for cardiologists is to support hemodynamics until response to chemotherapy occurs. In the article the issue of diagnostics, risk stratification and treatment of primary cardiac amyloidosis is addressed.

show abstract